- Home
- ENGN vs LRMR Comparison
ENGN vs LRMR Comparison
Compare ENGN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- LRMR
- Stock Information
- Founded
- ENGN 1999
- LRMR N/A
- Country
- ENGN Canada
- LRMR United States
- Employees
- ENGN N/A
- LRMR N/A
- Industry
- ENGN
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- LRMR Health Care
- Exchange
- ENGN Nasdaq
- LRMR Nasdaq
- Market Cap
- ENGN 321.5M
- LRMR 309.8M
- IPO Year
- ENGN N/A
- LRMR N/A
- Fundamental
- Price
- ENGN $5.97
- LRMR $3.96
- Analyst Decision
- ENGN Buy
- LRMR Strong Buy
- Analyst Count
- ENGN 8
- LRMR 8
- Target Price
- ENGN $21.50
- LRMR $17.88
- AVG Volume (30 Days)
- ENGN 217.5K
- LRMR 1.3M
- Earning Date
- ENGN 09-11-2025
- LRMR 10-29-2025
- Dividend Yield
- ENGN N/A
- LRMR N/A
- EPS Growth
- ENGN N/A
- LRMR N/A
- EPS
- ENGN N/A
- LRMR N/A
- Revenue
- ENGN N/A
- LRMR N/A
- Revenue This Year
- ENGN N/A
- LRMR N/A
- Revenue Next Year
- ENGN N/A
- LRMR N/A
- P/E Ratio
- ENGN N/A
- LRMR N/A
- Revenue Growth
- ENGN N/A
- LRMR N/A
- 52 Week Low
- ENGN $2.65
- LRMR $1.61
- 52 Week High
- ENGN $11.00
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- ENGN 72.82
- LRMR 54.10
- Support Level
- ENGN $5.52
- LRMR $3.78
- Resistance Level
- ENGN $6.54
- LRMR $4.26
- Average True Range (ATR)
- ENGN 0.53
- LRMR 0.27
- MACD
- ENGN 0.12
- LRMR -0.00
- Stochastic Oscillator
- ENGN 76.64
- LRMR 55.14
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.